Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA.

Trial Profile

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Apremilast (Primary) ; Tumour necrosis factor alpha inhibitors
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CATARA
  • Most Recent Events

    • 11 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 27 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top